NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Neuphoria Therapeutics Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026
$3.31+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $17.90M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
36.8%
2M of 5M shares
Institutional holders
22
6 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 875,328 | 16.30% | 13D (active) amendment | Dec 2, 2025 |
| Weston Nichols | 875,328 | 16.30% | 13D (active) amendment | Dec 26, 2025 |
| AdvisorShares Trust | 312,895 | 5.78% | 13G (passive) | Sep 30, 2026 |
| Shay Capital LLC | 171,629 | 7.30% | 13G (passive) | Oct 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NEUP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 875,328 | 16.18% | $3.83M | – | 0.44% |
| AdvisorShares Investments LLC | 252,909 | 4.67% | $1.11M | +97,542 | 0.13% |
| Vanguard Capital Management LLC | 173,488 | 3.21% | $758.14K | +74,972 | 0.00% |
| Shay Capital LLC | 155,822 | 2.88% | $680.94K | +4,812 | 0.04% |
| Balyasny Asset Management L.P. | 142,228 | 2.63% | $621.54K | +45 | 0.00% |
| Citadel Advisors LLC | 72,559 | 1.34% | $317.08K | +53,228 | 0.00% |
| Geode Capital Management, LLC | 49,516 | 0.92% | $216.38K | −2,491 | 0.00% |
| Ikarian Capital, LLC | 47,443 | 0.88% | $207.33K | – | 0.02% |
| Vanguard Fiduciary Trust Co | 33,806 | 0.62% | $147.73K | +217 | 0.00% |
| ADAR1 Capital Management, LLC | 30,000 | 0.55% | $131.10K | – | 0.01% |
| FNY Investment Advisers, LLC | 26,500 | 0.49% | $115 | – | 0.04% |
| Renaissance Technologies LLC | 25,500 | 0.47% | $111.44K | New | 0.00% |
| XTX Topco Ltd | 23,089 | 0.43% | $100.90K | New | 0.00% |
| Hrt Financial LP | 22,865 | 0.42% | $99 | New | 0.00% |
| Jane Street Group, LLC | 14,903 | 0.28% | $65.13K | New | 0.00% |
| Boothbay Fund Management, LLC | 14,000 | 0.26% | $61.18K | – | 0.00% |
| Commonwealth Equity Services, LLC | 11,222 | 0.21% | $49.04K | – | 0.00% |
| Northern Trust Corp | 10,610 | 0.20% | $46.37K | New | 0.00% |
| Merck & Co., Inc. | 10,027 | 0.19% | $43.82K | – | 0.01% |
| UBS Group AG | 2,117 | 0.04% | $9.25K | −199 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 2M | 36.8% | 6 / 6 | 2 / 3 | 0M | 0M |
| Q1 2026 | 19 | 2M | 32.5% | 6 / 5 | 1 / 7 | 0M | 0M |
| Q4 2025 | 21 | 1M | 27.1% | 9 / 9 | 1 / 3 | 1M | 0M |
| Q3 2025 | 15 | 0M | 3.6% | 9 / 2 | 1 / 3 | 0M | 0M |
| Q2 2025 | 9 | 0M | 3.3% | 2 / 1 | 2 / 0 | 0M | 0M |
| Q1 2025 | 7 | 0M | 3.0% | 3 / 0 | 1 / 4 | 0M | 0M |
| Q4 2024 | 8 | 0M | 1.5% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NEUP | Value | % of fund | As of |
|---|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 252,909 | 4.67% | $1.11M | 2.49% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 110,171 | 2.04% | $481.45K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 63,317 | 1.17% | $276.70K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 31,546 | 0.58% | $167.51K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,036 | 0.15% | $42.67K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,427 | 0.04% | $12.89K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,001 | 0.04% | $10.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Spyros Papapetropoulos | President and CEO, Director | 5,999,940 | 110.88% | Sep 2, 2025 |
| Peter Miles Winston Davies | Director | 269,984 | 4.99% | Jan 21, 2026 |
| Jane Ryan | Director | – | – | Jan 21, 2026 |
| Alan Fisher | Director | 100,000 | 1.85% | Jan 21, 2026 |
| David Ian Wilson | Director | 251,939 | 4.66% | Jan 21, 2026 |
| Weston Nichols | 10% owner | – | – | Oct 23, 2025 |
| Capital Management LP Lynx1 | 10% owner | 236,218 | 4.37% | Oct 23, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital Management LP Lynx1 10% owner | Oct 21, 2025 | Buy | +639,110 | $5.14 | $3.29M | 875,328 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.